Tag: Watchman FLX
Boston shares plethora of new findings on Farapulse PFA and Watchman...
Boston Scientific Corporation has announced data supporting the use of the company's Farapulse pulsed field ablation (PFA) platform and Watchman left atrial appendage closure...
LAA closure device non-inferior to blood thinners in lowering stroke risk...
For patients with non-valvular atrial fibrillation (AF) who had no contraindications to taking oral anticoagulants, the use of a device to close off the...
Boston Scientific announces late-breaking data on Farapulse and Watchman FLX technologies...
At the 2025 European Society of Cardiology (ESC) congress (29 August–1 September, Madrid, Spain), Boston Scientific shared two late-breaking presentations pertaining to its Farapulse...
New data presented on Farapulse and Watchman FLX devices at AF...
Boston Scientific announced data supporting the use of the Farapulse pulsed field ablation (PFA) system and the Watchman FLX left atrial appendage closure (LAAC) device,...
AHA 2024: OPTION trial reports positive outcomes for Watchman FLX at...
Three-year results from the OPTION clinical trial, comparing the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) system to oral anticoagulation for stroke...
Medtech insight: Trial pipeline underpins growth strategy for Watchman LAAC device
Investment in a programme of clinical trials will underpin Boston Scientific’s strategy to expand the uptake of its Watchman left atrial appendage closure (LAAC)...
CRT 2022: SURPASS registry shows low rate of adverse events associated...
Results from a new analysis assessing real-world outcomes with the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) demonstrated a low rate of...
Next-generation Watchman LAAC device gains US FDA approval
Boston Scientific has received US Food and Drug Administration (FDA) approval for the Watchman FLX left atrial appendage closure (LAAC) device. The device is...